NCT07208773RecruitingPhase 1/2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- First submitted
- 28 Sept 2025
- Start date
- 29 Oct 2025
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Diseases
- Lung cancer
- NCT number
- NCT07208773
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 260
- From 29 Oct 2025 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).
- Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.
- Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) \[anti-PD-(L)1\] or other immune checkpoint inhibitors.
- History of bleeding tendency or coagulation disorders and/or clinically significant bleeding symptoms or risks within 4 weeks before randomization.
- Clinically significant concurrent pulmonary diseases.
Other illness
- Active autoimmune disease requiring systemic treatment.
- Patients with uncontrolled or clinically significant cardiovascular diseases.
- Known to have active pulmonary tuberculosis. Other protocol-defined inclusion/ exclusion criteria may apply
Other
- Suitable for local curative treatment.
- Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels.
- Brain metastases or spinal cord compression.
Who the study is looking for
- Age ≥ 18 years old.
- Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.
- ECOG PS score is 0 or 1.
- Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.